Breast cancer drug shown to reduce recurrence risk

Agence France-Presse

<div class="embed-wrap"><figure data-feedback="fb:likes,fb:comments"><img alt="EPA-EFE/Sáshenka Gutiérrez" src="https://sa.kapamilya.com/absnews/abscbnnews/media/2023/life/06/02/20230602-breast-cancer-patient-epa-efe.jpg"/><figcaption>Angeles Arreola, a breast cancer patient, shows her breast, in Mexico City, Mexico, 17 October 2022 (Issued 19 October 2022). <em>EPA-EFE/Sáshenka Gutiérrez</em></figcaption></figure></div><p>WASHINTON—Even when the disease is caught early, breast cancer recurrence is relatively commonplace -- and for survivors, the prospect can be daunting.</p><p>A drug developed by Swiss pharmaceutical maker Novartis reduced this risk by a quarter in a large group of early-stage survivors of the most common type of breast cancer, according to clinical trial results presented Friday at the American Society of Clinical Oncology&#x27;s (ASCO) annual meeting, offering patients new hope.</p><p>The study of ribociclib, which belongs to a newer class of drugs known as molecularly targeted therapies, was described as a &quot;very important and practice-changing clinical trial,&quot; by ASCO expert Rita Nanda, who was not involved in the research.</p><p>The majority of the two million new breast cancers diagnosed globally are in the early phases of the disease, defined as stages I through III.</p><p>&quot;The current standard of therapy for these patients is surgery followed by chemotherapy... or radiation, then followed by between five and 10 years of hormonal blockade by various endocrine therapies,&quot; lead author Dennis Slamon of the UCLA Jonsson Comprehensive Cancer Center told reporters.</p><ul class="op-related-articles">	<li><a href="https://news.abs-cbn.com/spotlight/04/04/23/doh-2700-filipinos-got-skin-cancer-from-2011-2021">DOH: Over 2,700 Filipinos diagnosed with skin cancer from 2011-2021</a></li></ul><p>But recurrence is as high as more than one in three people for stage I, and more than one in two in stage III, with cancer sometimes returning decades later.</p><p>The clinical trial involved more than 5,100 people with stage II and stage III forms of HR-positive, HER2-negative breast cancer, which is the most common subtype, making up nearly 70 percent of all breast cancer cases in the United States.</p><p>Half the patients received ribociclib -- marketed under the brand name Kisqali -- as well as hormonal therapy, while the other half received only hormonal therapy. They continued for a treatment period of three years.</p><p>But the trial was halted early because a significant difference in outcomes between the two groups became apparent, and it would not have been ethical to allow the hormone therapy-only group to miss out on the more effective treatment.</p><p>Overall, 7.4 percent of patients in the ribociclib group experienced a recurrence against 9.2 percent of patients in the hormone therapy-only group, which means an approximate risk reduction of 25 percent.</p><p>&quot;Ribociclib also showed more favorable outcomes in overall survival, recurrence-free survival, and distant disease-free survival,&quot; a press statement said.</p><ul class="op-related-articles">	<li><a href="https://news.abs-cbn.com/spotlight/05/19/23/cervical-cancer-is-2nd-most-common-cancer-among-filipinas-expert">Cervical cancer is second most common cancer among Filipinas - expert</a></li></ul><p>While ribociclib, which is already widely approved around the world, has previously shown benefits for people with metastatic breast cancer, the new study was able to demonstrate it also improves outcomes for people with earlier stages, including those with cancer that hasn&#x27;t yet spread to the lymph nodes.</p><p>The most common side effects were abnormally low counts of a type of white blood cell called neutrophils, as well as joint pain. Less common effects included gastrointestinal issues and fatigue.</p><p>Ribociclib works by disrupting proteins in breast cancer cells responsible for cell division.</p><p>Novartis plans to continue to study longer-term outcomes.</p><div><strong>RELATED VIDEO</strong></div><figure class="op-interactive"><iframe height="315" src="https://www.youtube.com/embed/z2HRu4d0ExU?enablejsapi=1" width="560"></iframe></figure><div class="iwantbar">Watch more News on <a href="https://www.iwanttfc.com/#!/browse/Genres/News/tag_id_genres/id_news" target="_blank">iWantTFC</a></div>

Breast cancer recurrence is relatively commonplace -- and for survivors, the prospect can be daunting.

Breast cancer drug shown to reduce recurrence risk | ABS-CBN

Halalan 2025

Entertainment

News

Metro.Style

Sports

More

Traffic

Spotlight

Breast cancer drug shown to reduce recurrence risk

Breast cancer drug shown to reduce recurrence risk

Agence France-Presse

Published Jun 02, 2023 11:28 PM PHT

Read More:

breast cancer

ribociclib

cancer cells

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

Terms of Service

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Advertise with Us

Privacy Policy

Terms of Service

© 2025 ABS-CBN Corporation. All Rights Reserved.